Gastrointestinal stromal tumors (GIST) were the first type of soft tissue sarcoma (STS) to be treated with the targeted tyrosine kinase inhibitor (TKI) imatinib. Since those dramatic results were revealed, many second- and third-generation TKIs have been shown to be active in GIST, and other targeted therapies have been used for numerous types of STS.
Across this field of rare, heterogeneous malignancies, Dr George Demetri, from Dana-Farber Cancer Institute in Boston, tracks the expanding number of targeted therapies for STS, including neurotrophic tyrosine receptor kinase (NTRK) fusion inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and a variety of more recent inhibitors that have changed the landscape and significantly improved outcomes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Targeted Therapies for Soft Tissue Sarcomas - Medscape - Jul 07, 2023.
Comments